CA3148592A1 - Selective estrogen receptor degrader - Google Patents
Selective estrogen receptor degrader Download PDFInfo
- Publication number
- CA3148592A1 CA3148592A1 CA3148592A CA3148592A CA3148592A1 CA 3148592 A1 CA3148592 A1 CA 3148592A1 CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A CA3148592 A CA 3148592A CA 3148592 A1 CA3148592 A1 CA 3148592A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- cancer
- less
- chromen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921029554 | 2019-07-22 | ||
| IN201921029554 | 2019-07-22 | ||
| PCT/IB2020/056914 WO2021014386A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3148592A1 true CA3148592A1 (en) | 2021-01-28 |
Family
ID=71842730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3148592A Pending CA3148592A1 (en) | 2019-07-22 | 2020-07-22 | Selective estrogen receptor degrader |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11014915B2 (https=) |
| EP (1) | EP4003525A1 (https=) |
| JP (1) | JP2022541938A (https=) |
| KR (1) | KR20220046586A (https=) |
| CN (1) | CN114302879A (https=) |
| AU (1) | AU2020317099A1 (https=) |
| BR (1) | BR112022001285A2 (https=) |
| CA (1) | CA3148592A1 (https=) |
| CL (1) | CL2022000156A1 (https=) |
| IL (1) | IL290036A (https=) |
| MX (1) | MX2022001013A (https=) |
| PE (1) | PE20221588A1 (https=) |
| PH (1) | PH12022550182A1 (https=) |
| WO (1) | WO2021014386A1 (https=) |
| ZA (1) | ZA202201157B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021003440A2 (pt) * | 2018-09-07 | 2021-05-18 | Sanofi | sais de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil) pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxilato de metila e seu processo de preparação |
| CN114127054B (zh) | 2019-07-22 | 2024-04-09 | 勃林格殷格翰国际有限公司 | 作为用于治疗炎性气道或纤维化疾病的自分泌运动因子(atx)调节剂的n-甲基、n-(6-(甲氧基)哒嗪-3-基)胺衍生物 |
| KR20220046586A (ko) * | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
| CA3243621A1 (en) * | 2022-02-01 | 2023-08-10 | Eli Lilly And Company | METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS |
| CN119176799B (zh) * | 2024-09-19 | 2025-10-03 | 晨伫(杭州)生物科技有限责任公司 | 色烯衍生物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395842A (en) | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
| EP0470310B1 (en) | 1990-08-09 | 1995-11-29 | Council of Scientific and Industrial Research | Novel benzopyrans and process for their production |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| US5407947A (en) | 1993-11-05 | 1995-04-18 | Eli Lilly And Company | Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans |
| US5389646A (en) | 1993-12-30 | 1995-02-14 | Zymogenetics, Inc. | Methods for treatment and prevention of bone loss using 2,3-benzopyrans |
| AU8102398A (en) | 1997-07-09 | 1999-02-08 | Central Drug Research Institute | (dl)-2,3-diaryl-2h-1-benzopyrans |
| DE10013782A1 (de) | 2000-03-15 | 2001-10-18 | Schering Ag | 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| RS56042B1 (sr) | 2010-06-10 | 2017-09-29 | Seragon Pharmaceuticals Inc | Modulatori estrogenih receptora i njihove upotrebe |
| WO2013090829A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| CA2915534A1 (en) * | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| CN103879283B (zh) * | 2014-03-10 | 2019-01-15 | 浙江吉利汽车研究院有限公司 | 一种电动车辆 |
| US20160175284A1 (en) * | 2014-12-18 | 2016-06-23 | Genentech, Inc. | Estrogen receptor modulators and uses thereof |
| WO2016174551A1 (en) | 2015-04-27 | 2016-11-03 | Pfizer Inc. | Anti-estrogenic compounds |
| US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
| WO2017072792A1 (en) * | 2015-10-27 | 2017-05-04 | Sun Pharma Advanced Research Company Limited | Novel heterocyclic antiestrogens |
| KR20220046586A (ko) * | 2019-07-22 | 2022-04-14 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 선택적 에스트로겐 수용체 분해제 |
-
2020
- 2020-07-22 KR KR1020227005904A patent/KR20220046586A/ko not_active Ceased
- 2020-07-22 AU AU2020317099A patent/AU2020317099A1/en not_active Abandoned
- 2020-07-22 JP JP2022504655A patent/JP2022541938A/ja active Pending
- 2020-07-22 CN CN202080053315.6A patent/CN114302879A/zh active Pending
- 2020-07-22 US US16/936,022 patent/US11014915B2/en active Active
- 2020-07-22 WO PCT/IB2020/056914 patent/WO2021014386A1/en not_active Ceased
- 2020-07-22 EP EP20747136.8A patent/EP4003525A1/en not_active Withdrawn
- 2020-07-22 CA CA3148592A patent/CA3148592A1/en active Pending
- 2020-07-22 PE PE2022000135A patent/PE20221588A1/es unknown
- 2020-07-22 BR BR112022001285A patent/BR112022001285A2/pt not_active IP Right Cessation
- 2020-07-22 PH PH1/2022/550182A patent/PH12022550182A1/en unknown
- 2020-07-22 MX MX2022001013A patent/MX2022001013A/es unknown
-
2021
- 2021-05-05 US US17/308,501 patent/US20210261534A1/en not_active Abandoned
-
2022
- 2022-01-22 CL CL2022000156A patent/CL2022000156A1/es unknown
- 2022-01-23 IL IL290036A patent/IL290036A/en unknown
- 2022-01-25 ZA ZA2022/01157A patent/ZA202201157B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202201157B (en) | 2023-07-26 |
| CL2022000156A1 (es) | 2022-11-18 |
| WO2021014386A1 (en) | 2021-01-28 |
| PE20221588A1 (es) | 2022-10-10 |
| JP2022541938A (ja) | 2022-09-28 |
| PH12022550182A1 (en) | 2022-11-14 |
| EP4003525A1 (en) | 2022-06-01 |
| BR112022001285A2 (pt) | 2022-03-22 |
| KR20220046586A (ko) | 2022-04-14 |
| US20210024504A1 (en) | 2021-01-28 |
| US11014915B2 (en) | 2021-05-25 |
| AU2020317099A1 (en) | 2022-02-24 |
| CN114302879A (zh) | 2022-04-08 |
| IL290036A (en) | 2022-03-01 |
| US20210261534A1 (en) | 2021-08-26 |
| MX2022001013A (es) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11014915B2 (en) | Selective estrogen receptor degrader | |
| US20240131013A1 (en) | TETRAHYDRO-1H-PYRIDO[3,4-b]INDOLE ANTI-ESTROGENIC DRUGS | |
| CN1181077A (zh) | 苯并吡喃类化合物及其使用方法 | |
| CZ299721B6 (cs) | Lécivo pro lécení mocové inkontinence | |
| KR20160021281A (ko) | 아제티딘 에스트로겐 수용체 조절제 및 이의 용도 | |
| CN107406433A (zh) | 用于治疗癌症的2,3‑二苯基色烯的衍生物 | |
| CN105324115A (zh) | 雌激素受体调节剂及其用途 | |
| US20040192763A1 (en) | NMDA NR2B antagonists for treatment | |
| US20040110791A1 (en) | Novel arylaminopropane analogues and their use for the treatment of glaucoma | |
| Halama et al. | Improved process for the preparation of montelukast: development of an efficient synthesis, identification of critical impurities and degradants | |
| US7632963B2 (en) | Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate | |
| TW202300492A (zh) | 選擇性雌激素受體降解劑 | |
| US7655653B2 (en) | Tetrahydrobenzfluorene derivatives | |
| WO2004031125A1 (ja) | スピロ化合物、それを含有する医薬組成物及び該化合物の中間体 | |
| US20030125571A1 (en) | Optically active chroman and thiochroman derivatives | |
| JP3294574B2 (ja) | 光学的に純粋なアンドロゲンメディエーター | |
| RU2855858C2 (ru) | ТЕТРАГИДРО-1H-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА | |
| WO2025255358A1 (en) | Solid forms of posiphen d-tartrate and processes of preparation thereof | |
| CN101134739A (zh) | 新的β-内酰胺类化合物及其制备方法及其药物用途 | |
| HK40056233A (en) | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs | |
| US20100009949A1 (en) | Novel method | |
| HK1247195A1 (en) | Derivatives of 2,3-diphenylchromene useful for the treatment of cancer | |
| HK1214532B (zh) | 雌激素受體調節劑及其用途 | |
| HK1124337A (en) | Nuclear receptor binding agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251204 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260109 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260129 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260204 |